MedDataX Logo

Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease

NCT ID: NCT00412048

Last Updated: 2012-11-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the protocol is to study the resting brain activation profile of 3 groups of people, using a new fMRI procedure, called fMRI-SAM. fMRI-SAM will be applied to 25 Alzheimer's disease (AD) patients, 25 patients suffering from amnestic - mild cognitive impairment (MCI) - a clinical picture which may be a prodromal form of AD - and 60 healthy controls. The first analysis of the data will search differences of brain activation profiles between the 3 groups. In the second step, the investigators will study the predictive value of fMRI-SAM to detect MCI patients who will later convert to AD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALZHEIMER DISEASE

Group Type OTHER

fMRI to detect MCI patients who will convert to Alzheimer's disease

Intervention Type PROCEDURE

There is a fMRI to be realized in the 3 arms. No drug is administered

MOLD COGNITIVE IMPAIRMENT

Group Type OTHER

fMRI to detect MCI patients who will convert to Alzheimer's disease

Intervention Type PROCEDURE

There is a fMRI to be realized in the 3 arms. No drug is administered

CONTROLS

Group Type OTHER

fMRI to detect MCI patients who will convert to Alzheimer's disease

Intervention Type PROCEDURE

There is a fMRI to be realized in the 3 arms. No drug is administered

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fMRI to detect MCI patients who will convert to Alzheimer's disease

There is a fMRI to be realized in the 3 arms. No drug is administered

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Alzheimer's disease of mild to moderate severity (25 patients)
* Amnestic MCI patients (25 patients)
* 55-75 year-old patients

Exclusion Criteria

* Any other cause of dementia for AD patients
* Any stroke
* Any disease with a negative vital prognosis
Minimum Eligible Age

55 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francois Sellal, MD

Role: PRINCIPAL_INVESTIGATOR

Hôpitaux Universitaires de Strasbourg

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3659

Identifier Type: -

Identifier Source: org_study_id